Thoracic Cancer · 2018 · 11 citations · 25 references
MedicineGeriatric MedicineOncologyChemotherapyMedical OncologyThoracic OncologyGeriatric OncologyLung Cancer PharmacotherapyMedian AgeSmall Cell Lung Cancer TherapySmall Cell Lung Cancer TreatmentSurvival Rates
BACKGROUND: Carboplatin plus etoposide (CE) is a standard treatment for elderly patients with extensive-disease small cell lung cancer (ED-SCLC). However, amrubicin monotherapy (AMR) may be a feasible alternative. We compared the efficacies and safety profiles of CE and AMR for ED-SCLC in elderly patients and chemotherapy-naive patients with poor performance status (PS). METHODS: The records of SCLC patients who received CE or AMR as first-line chemotherapy were retrospectively reviewed and their treatment outcomes evaluated. RESULTS: Eighty-four patients (median age 72 years; 42 each received CR and AMR) were analyzed; 34 patients had a PS score of 2. There were no significant differences in patient characteristics between the treatment groups. The median progression-free survival rates of patients in the CE and AMR groups were 5.8 and 4.8 months, respectively (P = 0.04); overall survival was 14.0 and 8.5 months, respectively (P = 0.089). Twenty-three CE group patients received AMR as second-line chemotherapy; their median overall survival from first-line chemotherapy was 18.5 months. Grade 3 or higher neutropenia occurred more frequently in patients treated with AMR (64% vs. 40%; P = 0.02), as did febrile neutropenia (14% vs. 7%). CONCLUSIONS: CE remains a suitable first-line treatment for ED-SCLC in elderly patients or those with poor PS in comparison with AMR.
25
Akira Inoue, Shunichi Sugawara, Koichi Yamazaki et al. · Journal of Clinical Oncology · 2008 · 235 citations
Medicine, Oncology, Pharmacology +11
Hiroaki Okamoto, Kenji Watanabe, Hiroshi Kunikane et al. · British Journal of Cancer · 2007 · 212 citations · Full text
Medicine, Oncology, Pharmacology +15
Trends in Lung Cancer Incidence by Histological Type in Osaka, Japan
Yasuhiro Toyoda, Tomio Nakayama, Akiko Ioka et al. · Japanese Journal of Clinical Oncology · 2008 · 123 citations · Full text